107 related articles for article (PubMed ID: 20658618)
1. Retinoic acid enhances sensitivity of neuroblastoma cells for imatinib mesylate.
Neumann I; Foell JL; Bremer M; Volkmer I; Korholz D; Burdach S; Staege MS
Pediatr Blood Cancer; 2010 Sep; 55(3):464-70. PubMed ID: 20658618
[TBL] [Abstract][Full Text] [Related]
2. c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571.
Vitali R; Cesi V; Nicotra MR; McDowell HP; Donfrancesco A; Mannarino O; Natali PG; Raschellà G; Dominici C
Int J Cancer; 2003 Aug; 106(2):147-52. PubMed ID: 12800187
[TBL] [Abstract][Full Text] [Related]
3. Slug (SNAI2) down-regulation by RNA interference facilitates apoptosis and inhibits invasive growth in neuroblastoma preclinical models.
Vitali R; Mancini C; Cesi V; Tanno B; Mancuso M; Bossi G; Zhang Y; Martinez RV; Calabretta B; Dominici C; Raschellà G
Clin Cancer Res; 2008 Jul; 14(14):4622-30. PubMed ID: 18628477
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer?
Wiedmann M; Kreth F; Feisthammel J; Deininger M; Mössner J; Caca K
Anticancer Drugs; 2003 Oct; 14(9):751-60. PubMed ID: 14551510
[TBL] [Abstract][Full Text] [Related]
5. The G-quadruplex ligand, SYUIQ-FM05, targets proto-oncogene c-kit transcription and induces apoptosis in K562 cells.
Shen FH; Jin J; Li J; Wang Y; Zhu SH; Lu YJ; Ou TM; Huang ZS; Huang M; Huang ZY
Pharm Biol; 2013 Apr; 51(4):447-54. PubMed ID: 23363047
[TBL] [Abstract][Full Text] [Related]
6. [In vitro effect of STI571 on expression of c-kit in bone marrow cells from patients with acute non-lymphocytic leukemia].
Tan Tai LF; Yi ZS; Feng R
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):256-8. PubMed ID: 12844407
[TBL] [Abstract][Full Text] [Related]
7. c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571).
Hotfilder M; Lanvers C; Jürgens H; Boos J; Vormoor J
Cancer Chemother Pharmacol; 2002 Aug; 50(2):167-9. PubMed ID: 12172985
[TBL] [Abstract][Full Text] [Related]
8. Effect of STI-571 (imatinib mesylate) in combination with retinoic acid and gamma-irradiation on viability of neuroblastoma cells.
Rössler J; Zambrzycka I; Lagodny J; Kontny U; Niemeyer CM
Biochem Biophys Res Commun; 2006 Apr; 342(4):1405-12. PubMed ID: 16524560
[TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
[TBL] [Abstract][Full Text] [Related]
10. CD117 (c-kit) expression on CD34+ cells participates in the cytogenetic response to imatinib in patients with chronic myeloid leukemia in the first chronic phase.
Dybko J; Haus O; Jazwiec B; Urbaniak J; Wozniak M; Kaczmar-Dybko A; Urbaniak-Kujda D; Kapelko-Slowik K; Kuliczkowski K
Acta Haematol; 2014; 132(2):166-71. PubMed ID: 24577437
[TBL] [Abstract][Full Text] [Related]
11. Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis.
Rassidakis GZ; Georgakis GV; Oyarzo M; Younes A; Medeiros LJ
Mod Pathol; 2004 Aug; 17(8):946-53. PubMed ID: 15105813
[TBL] [Abstract][Full Text] [Related]
12. Exposure of neuroblastoma cell lines to imatinib results in the upregulation of the CDK inhibitor p27(KIP1) as a consequence of c-Abl inhibition.
Lupino E; Ramondetti C; Buccinnà B; Piccinini M
Biochem Pharmacol; 2014 Nov; 92(2):235-50. PubMed ID: 25264277
[TBL] [Abstract][Full Text] [Related]
13. Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer.
Cardoso HJ; Vaz CV; Correia S; Figueira MI; Marques R; Maia CJ; Socorro S
Prostate; 2015 Jun; 75(9):923-35. PubMed ID: 25786656
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
Te Kronnie G; Timeus F; Rinaldi A; Crescenzio N; Spinelli M; Rosolen A; Ricotti E; Basso G
Int J Mol Med; 2004 Sep; 14(3):373-82. PubMed ID: 15289888
[TBL] [Abstract][Full Text] [Related]
15. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice.
Knight B; Tirnitz-Parker JE; Olynyk JK
Gastroenterology; 2008 Sep; 135(3):969-79, 979.e1. PubMed ID: 18602920
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H
Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856
[TBL] [Abstract][Full Text] [Related]
17. Imatinib targeting of KIT-mutant oncoprotein in melanoma.
Jiang X; Zhou J; Yuen NK; Corless CL; Heinrich MC; Fletcher JA; Demetri GD; Widlund HR; Fisher DE; Hodi FS
Clin Cancer Res; 2008 Dec; 14(23):7726-32. PubMed ID: 19047099
[TBL] [Abstract][Full Text] [Related]
18. Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation.
Stahtea XN; Roussidis AE; Kanakis I; Tzanakakis GN; Chalkiadakis G; Mavroudis D; Kletsas D; Karamanos NK
Int J Cancer; 2007 Dec; 121(12):2808-14. PubMed ID: 17721919
[TBL] [Abstract][Full Text] [Related]
19. All-trans retinoic acid induces COX-2 and prostaglandin E2 synthesis in SH-SY5Y human neuroblastoma cells: involvement of retinoic acid receptors and extracellular-regulated kinase 1/2.
Alique M; Herrero JF; Lucio-Cazana FJ
J Neuroinflammation; 2007 Jan; 4():1. PubMed ID: 17204142
[TBL] [Abstract][Full Text] [Related]
20. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
